+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Nucleic Acids for Molecular Diagnosis Market by Product (Instruments, Reagents and Kits, Services), Technology (Microarrays, Next Generation Sequencing, Pcr), Application, Nucleic Acid Type, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6146669
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Nucleic acids lie at the heart of modern molecular diagnostics, serving as the fundamental biomolecules that encode genetic information and enable precise detection of disease markers. By examining DNA and RNA sequences, clinicians and researchers can uncover the molecular underpinnings of health and disease, paving the way for personalized medicine approaches. Recent technological advancements have dramatically increased the sensitivity and specificity of nucleic acid assays, empowering diagnostic laboratories to detect even minute genetic variations with unprecedented accuracy.

As we enter a new era where precision is paramount, the integration of advanced sequencing platforms, digital PCR technologies, and high-throughput microarrays has expanded the scope and scale of molecular diagnostics. Laboratories can now process larger volumes of samples more efficiently, reducing turnaround times and enhancing patient outcomes. This revolution in diagnostic capability is further underpinned by innovations in bioinformatics, which translate raw sequence data into clinically actionable insights through sophisticated data analysis pipelines.

Explore the groundbreaking technological and methodological shifts in molecular diagnostics driven by advancements in nucleic acid analysis and sequencing innovation

The landscape of molecular diagnostics is undergoing transformative shifts as next generation sequencing platforms evolve from research tools into routine clinical instruments. What once required specialized laboratories now fits within streamlined workflows, enabling broader access to comprehensive genomic profiling. Concurrently, digital PCR has emerged as a game-changer, offering absolute quantification of nucleic acids without reliance on standard curves and significantly improving detection limits for rare mutations and minimal residual disease.

At the same time, microarray technology continues to adapt, integrating with novel sample preparation protocols and becoming more cost-effective for large-scale gene expression and genotyping applications. The convergence of automation and modular sample-to-answer systems has reduced hands-on time, minimized error rates, and enabled decentralized testing in near-patient settings. These methodological advances are complemented by the rise of cloud-based bioinformatics solutions, which facilitate real-time data analysis, collaborative interpretation, and seamless integration with electronic health records. Collectively, these shifts are redefining how molecular diagnostics deliver value to healthcare providers and patients alike.

Understand the compounded consequences of the 2025 United States tariffs on nucleic acid reagents, instrumentation, and services across global supply chains

The implementation of the 2025 United States tariffs on imported reagents, kits, and instrumentation has exerted multifaceted financial pressures on molecular diagnostics stakeholders worldwide. Suppliers have responded by adjusting pricing strategies, while end users face elevated operational costs that may slow adoption rates of cutting-edge assays. Amid these headwinds, procurement teams are diversifying their supplier networks and negotiating longer-term contracts to stabilize input costs and secure critical materials.

Simultaneously, manufacturers are reevaluating global supply chain configurations, with some increasing onshore production capacity and others seeking tariff-exempt regions to circumvent additional duties. Collaborative initiatives with contract manufacturing organizations have gained traction as a means to mitigate exposure to tariff fluctuations. Regulatory agencies and industry consortia are also exploring relief measures, advocating for tariff exemptions on essential clinical diagnostics components to sustain innovation and protect patient care services.

Reveal critical insights into the molecular diagnostics market through a multifaceted segmentation lens covering products, technologies, applications, nucleic acids, and end users

Analyzing the market through the lens of product segmentation highlights distinct dynamics across instruments, reagents and kits, and services. Instruments encompass microarray platforms, qPCR systems, and sequencers, each offering unique capabilities that meet varying throughput and sensitivity requirements. Reagents and kits span microarray kits, next generation sequencing library preparation kits, and PCR reagents, reflecting the evolving preferences for assay flexibility and protocol standardization. Complementing these are services that range from bioinformatics to laboratory and sequencing support, ensuring end-to-end solutions for complex genomic workflows.

From a technological standpoint, microarrays break down into gene expression and genotyping arrays, while next generation sequencing is categorized into RNA sequencing, targeted sequencing, and whole genome sequencing modalities. PCR technology itself differentiates into conventional PCR, digital PCR, and real-time PCR applications, each serving critical roles in quantitative and qualitative analyses. In application segmentation, genetic testing includes carrier, pharmacogenomic, and predictive assays. Infectious disease testing covers bacterial, parasitic, and viral disease detection, whereas oncology spans hematological and solid tumor testing, and prenatal assays divide into invasive and non-invasive methodologies.

Considering nucleic acid type segmentation, DNA-based diagnostics exploit both complementary DNA and genomic DNA, whereas RNA-focused approaches center on microRNA and mRNA analysis to capture gene expression profiles and regulatory RNA signatures. Finally, end user segmentation reflects the diverse market ecosystem, with academic and research institutions, biopharmaceutical companies, diagnostic laboratories, and hospitals and clinics each driving distinct demand patterns and influencing the pace of innovation.

Uncover pivotal regional dynamics shaping molecular diagnostics adoption and innovation across the Americas, Europe Middle East Africa, and Asia-Pacific markets

In the Americas, the mature regulatory landscape and established reimbursement frameworks have fostered rapid adoption of advanced nucleic acid-based diagnostics. The region’s robust network of academic research centers and leading biotechnology firms fuels continuous innovation, while public-private partnerships accelerate the translation of novel assays into clinical settings. Despite occasional pricing pressures and reimbursement challenges, the demand for precision diagnostics remains strong, driven by the prevalence of chronic diseases and a growing emphasis on personalized health management.

Europe, Middle East, and Africa collectively exhibit diverse market conditions characterized by varying regulatory environments and economic capabilities. Western Europe’s stringent quality standards and unified health technology assessment processes encourage uptake of high-complexity assays, whereas emerging markets within the region prioritize cost-effective testing solutions. Collaborative research initiatives between European centers of excellence and regional healthcare providers generate customized diagnostic panels suited to local disease burdens. In the Middle East and Africa, government-led screening programs and international funding efforts support expanded access to molecular diagnostics, often through public health initiatives addressing communicable diseases.

Asia-Pacific stands out as a rapidly expanding hub for nucleic acid diagnostics, propelled by large patient populations, growing healthcare expenditures, and proactive government policies that subsidize genomic medicine. Local manufacturers are scaling up production of cost-sensitive instruments and consumables, while multinational corporations form strategic alliances with regional distributors to enhance market reach. Increasing investments in digital infrastructure and telemedicine solutions further bolster decentralized testing models, particularly in remote and underserved areas where traditional laboratory networks are limited.

Gain strategic perspective on the leading companies driving breakthroughs in nucleic acid-based molecular diagnostics through innovation and market influence

Industry leaders are distinguished by their comprehensive portfolios that integrate high-performance sequencing platforms, advanced PCR systems, and specialized assay kits. These companies invest heavily in research and development to optimize sensitivity, reduce turnaround times, and expand multiplexing capabilities. Strategic partnerships with biopharmaceutical firms and diagnostic laboratories enable co-development of companion diagnostics, aligning assay innovation with therapeutic pipelines. In parallel, robust service offerings-including bioinformatics analysis, laboratory automation, and remote data management-provide end users with holistic solutions that streamline workflows and mitigate operational complexities.

Key organizations are also prioritizing digital transformation, offering cloud-based platforms that facilitate real-time monitoring of assay performance and enable seamless integration with laboratory information management systems. This digital ecosystem supports predictive maintenance of instruments, remote troubleshooting, and continuous software updates, thereby enhancing uptime and assay reproducibility. Furthermore, targeted acquisitions and collaborative research agreements are fortifying the competitive landscape, as firms acquire complementary technologies and expertise to address unmet needs in oncology, infectious diseases, and prenatal screening.

Implement targeted and actionable recommendations enabling industry leaders to optimize processes, partnerships, and investments in nucleic acid molecular diagnostics

Industry leaders should diversify their supply chains by establishing dual sourcing agreements and evaluating localized manufacturing options to minimize exposure to trade policy fluctuations. Investing in modular, scalable platforms will allow seamless adaptation to evolving assay requirements and accommodate fluctuating sample volumes. Collaborative partnerships with academic institutions and contract research organizations can accelerate validation cycles, promote knowledge exchange, and foster joint innovation projects that address emerging molecular targets.

Prioritizing the integration of artificial intelligence and machine learning into diagnostic pipelines will enhance data interpretation, support predictive analytics for disease progression, and improve diagnostic accuracy. Engaging proactively with regulatory bodies to advocate for standardized guidelines and tariff exemptions on critical reagents can safeguard supply continuity. Additionally, implementing comprehensive training programs for laboratory personnel and peer-to-peer knowledge networks will ensure consistent assay performance and drive adoption of novel technologies. Finally, expanding footprint into emerging markets through strategic alliances and flexible pricing models will unlock new revenue streams while addressing global health disparities.

Delve into the rigorous research methodology that underpins the analysis of nucleic acid molecular diagnostics ensuring comprehensive and credible insights

This analysis leverages a hybrid research methodology combining primary and secondary data sources. Primary research included in-depth interviews with C-level executives, laboratory directors, and senior scientists across leading diagnostic organizations. These expert insights were complemented by structured surveys that captured operational challenges, technology preferences, and procurement criteria. Secondary research encompassed a comprehensive review of peer-reviewed journals, white papers, regulatory filings, and public disclosures from instrument and reagent manufacturers.

Quantitative data was validated through triangulation across multiple sources to ensure reliability, while qualitative findings underwent thematic analysis to identify emerging trends and strategic imperatives. The segmentation framework was developed iteratively, with industry experts providing feedback to refine categorization criteria and ensure alignment with real-world market dynamics. Throughout the process, rigorous data governance policies were applied to maintain accuracy, transparency, and reproducibility of findings.

Synthesize the critical takeaways and future outlook for nucleic acid-driven molecular diagnostics highlighting key opportunities and challenges ahead

The integration of nucleic acid technologies into molecular diagnostics represents a paradigm shift toward more precise, personalized, and predictive healthcare solutions. As sequencing, digital PCR, and microarray platforms continue to mature, laboratories must navigate logistical and regulatory complexities, including trade policies and supply chain disruptions. Segmentation insights reveal diverse product, technology, and application-specific drivers, underscoring the importance of tailored strategies for different end users and geographic regions.

Looking ahead, collaboration between instrument manufacturers, reagent suppliers, service providers, and regulatory agencies will be critical to overcoming cost pressures and accelerating the adoption of high-impact assays. Embracing digital transformation and strategic alliances will empower stakeholders to unlock the full potential of genomic data, ultimately enhancing patient outcomes and driving sustained growth in molecular diagnostics. The continued convergence of innovation, policy alignment, and market expansion will define the next chapter in nucleic acid-powered diagnostics.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product
    • Instruments
      • Microarray Platforms
      • Qpcr Systems
      • Sequencers
    • Reagents And Kits
      • Microarray Kits
      • Ngs Library Preparation Kits
      • Pcr Reagents
    • Services
      • Bioinformatics Services
      • Laboratory Services
      • Sequencing Services
  • Technology
    • Microarrays
      • Gene Expression Arrays
      • Genotyping Arrays
    • Next Generation Sequencing
      • Rna Sequencing
      • Targeted Sequencing
      • Whole Genome Sequencing
    • Pcr
      • Conventional Pcr
      • Digital Pcr
      • Real-Time Pcr
  • Application
    • Genetic Testing
      • Carrier Testing
      • Pharmacogenomic Testing
      • Predictive Testing
    • Infectious Disease
      • Bacterial Disease Testing
      • Parasitic Disease Testing
      • Viral Disease Testing
    • Oncology
      • Hematological Cancer Testing
      • Solid Tumor Testing
    • Prenatal Testing
      • Invasive Prenatal Testing
      • Non-invasive Prenatal Testing
  • Nucleic Acid Type
    • Dna
      • Cdna
      • Genomic Dna
    • Rna
      • Microrna Analysis
      • Mrna Analysis
  • End User
    • Academic And Research
    • Biopharmaceutical Companies
    • Diagnostic Laboratories
    • Hospitals And Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Merck KGaA
  • Agilent Technologies, Inc.
  • Hologic, Inc.
  • PerkinElmer, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of CRISPR-based nucleic acid detection assays into point-of-care infectious disease testing
5.2. Rising adoption of digital droplet PCR for absolute quantification of circulating tumor DNA biomarkers
5.3. Development of multiplexed isothermal amplification platforms for rapid pathogen identification in decentralized settings
5.4. Expansion of RNA sequencing panels to include noncoding RNA signatures for early cancer screening applications
5.5. Implementation of lab automation workflows for high-throughput sample preparation in molecular diagnostic laboratories
5.6. Utilization of synthetic modified oligonucleotides to enhance stability and specificity in mRNA-based diagnostic assays
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Nucleic Acids for Molecular Diagnosis Market, by Product
8.1. Introduction
8.2. Instruments
8.2.1. Microarray Platforms
8.2.2. Qpcr Systems
8.2.3. Sequencers
8.3. Reagents And Kits
8.3.1. Microarray Kits
8.3.2. Ngs Library Preparation Kits
8.3.3. Pcr Reagents
8.4. Services
8.4.1. Bioinformatics Services
8.4.2. Laboratory Services
8.4.3. Sequencing Services
9. Nucleic Acids for Molecular Diagnosis Market, by Technology
9.1. Introduction
9.2. Microarrays
9.2.1. Gene Expression Arrays
9.2.2. Genotyping Arrays
9.3. Next Generation Sequencing
9.3.1. Rna Sequencing
9.3.2. Targeted Sequencing
9.3.3. Whole Genome Sequencing
9.4. Pcr
9.4.1. Conventional Pcr
9.4.2. Digital Pcr
9.4.3. Real-Time Pcr
10. Nucleic Acids for Molecular Diagnosis Market, by Application
10.1. Introduction
10.2. Genetic Testing
10.2.1. Carrier Testing
10.2.2. Pharmacogenomic Testing
10.2.3. Predictive Testing
10.3. Infectious Disease
10.3.1. Bacterial Disease Testing
10.3.2. Parasitic Disease Testing
10.3.3. Viral Disease Testing
10.4. Oncology
10.4.1. Hematological Cancer Testing
10.4.2. Solid Tumor Testing
10.5. Prenatal Testing
10.5.1. Invasive Prenatal Testing
10.5.2. Non-invasive Prenatal Testing
11. Nucleic Acids for Molecular Diagnosis Market, by Nucleic Acid Type
11.1. Introduction
11.2. Dna
11.2.1. Cdna
11.2.2. Genomic Dna
11.3. Rna
11.3.1. Microrna Analysis
11.3.2. Mrna Analysis
12. Nucleic Acids for Molecular Diagnosis Market, by End User
12.1. Introduction
12.2. Academic And Research
12.3. Biopharmaceutical Companies
12.4. Diagnostic Laboratories
12.5. Hospitals And Clinics
13. Americas Nucleic Acids for Molecular Diagnosis Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Nucleic Acids for Molecular Diagnosis Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Nucleic Acids for Molecular Diagnosis Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Thermo Fisher Scientific Inc.
16.3.2. QIAGEN N.V.
16.3.3. F. Hoffmann-La Roche Ltd.
16.3.4. Danaher Corporation
16.3.5. Abbott Laboratories
16.3.6. Bio-Rad Laboratories, Inc.
16.3.7. Merck KGaA
16.3.8. Agilent Technologies, Inc.
16.3.9. Hologic, Inc.
16.3.10. PerkinElmer, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NUCLEIC ACID TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NUCLEIC ACID TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET: RESEARCHAI
FIGURE 26. NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET: RESEARCHSTATISTICS
FIGURE 27. NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET: RESEARCHCONTACTS
FIGURE 28. NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAY PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAY PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY QPCR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY QPCR SYSTEMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SEQUENCERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SEQUENCERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAY KITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAY KITS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NGS LIBRARY PREPARATION KITS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NGS LIBRARY PREPARATION KITS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PCR REAGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PCR REAGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAGENTS AND KITS, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAGENTS AND KITS, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY LABORATORY SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY LABORATORY SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SEQUENCING SERVICES, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAYS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENE EXPRESSION ARRAYS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENOTYPING ARRAYS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENOTYPING ARRAYS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAYS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAYS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY RNA SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PCR, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY CARRIER TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY CARRIER TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PHARMACOGENOMIC TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PHARMACOGENOMIC TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY BACTERIAL DISEASE TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY BACTERIAL DISEASE TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PARASITIC DISEASE TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PARASITIC DISEASE TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY VIRAL DISEASE TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY VIRAL DISEASE TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY HEMATOLOGICAL CANCER TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY HEMATOLOGICAL CANCER TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SOLID TUMOR TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SOLID TUMOR TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRENATAL TESTING, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRENATAL TESTING, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NUCLEIC ACID TYPE, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY CDNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY CDNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENOMIC DNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENOMIC DNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DNA, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY RNA, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY RNA, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICRORNA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICRORNA ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MRNA ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MRNA ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY RNA, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY RNA, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY ACADEMIC AND RESEARCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY ACADEMIC AND RESEARCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAGENTS AND KITS, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAGENTS AND KITS, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAYS, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAYS, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PCR, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRENATAL TESTING, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRENATAL TESTING, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NUCLEIC ACID TYPE, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DNA, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY RNA, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY RNA, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAGENTS AND KITS, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAGENTS AND KITS, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAYS, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAYS, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PCR, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRENATAL TESTING, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRENATAL TESTING, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NUCLEIC ACID TYPE, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DNA, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY RNA, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY RNA, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 209. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 210. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 211. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 212. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 213. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAGENTS AND KITS, 2018-2024 (USD MILLION)
TABLE 214. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAGENTS AND KITS, 2025-2030 (USD MILLION)
TABLE 215. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 216. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 217. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 218. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 219. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAYS, 2018-2024 (USD MILLION)
TABLE 220. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAYS, 2025-2030 (USD MILLION)
TABLE 221. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 222. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 223. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
TABLE 224. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PCR, 2025-2030 (USD MILLION)
TABLE 225. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 226. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 227. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
TABLE 228. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
TABLE 229. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 230. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 231. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 232. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 233. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRENATAL TESTING, 2018-2024 (USD MILLION)
TABLE 234. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRENATAL TESTING, 2025-2030 (USD MILLION)
TABLE 235. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2024 (USD MILLION)
TABLE 236. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NUCLEIC ACID TYPE, 2025-2030 (USD MILLION)
TABLE 237. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
TABLE 238. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DNA, 2025-2030 (USD MILLION)
TABLE 239. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY RNA, 2018-2024 (USD MILLION)
TABLE 240. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY RNA, 2025-2030 (USD MILLION)
TABLE 241. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. CANADA NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 244. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 245. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 246. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 247. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAGENTS AND KITS, 2018-2024 (USD MILLION)
TABLE 248. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAGENTS AND KITS, 2025-2030 (USD MILLION)
TABLE 249. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 250. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 251. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 252. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 253. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAYS, 2018-2024 (USD MILLION)
TABLE 254. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY MICROARRAYS, 2025-2030 (USD MILLION)
TABLE 255. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 256. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 257. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
TABLE 258. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PCR, 2025-2030 (USD MILLION)
TABLE 259. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 260. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 261. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
TABLE 262. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY GENETIC TESTING, 2025-2030 (USD MILLION)
TABLE 263. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
TABLE 264. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
TABLE 265. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 266. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 267. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRENATAL TESTING, 2018-2024 (USD MILLION)
TABLE 268. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRENATAL TESTING, 2025-2030 (USD MILLION)
TABLE 269. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NUCLEIC ACID TYPE, 2018-2024 (USD MILLION)
TABLE 270. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY NUCLEIC ACID TYPE, 2025-2030 (USD MILLION)
TABLE 271. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DNA, 2018-2024 (USD MILLION)
TABLE 272. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY DNA, 2025-2030 (USD MILLION)
TABLE 273. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY RNA, 2018-2024 (USD MILLION)
TABLE 274. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY RNA, 2025-2030 (USD MILLION)
TABLE 275. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 276. MEXICO NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY INSTRUMENTS, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAGENTS AND KITS, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY REAGENTS AND KITS, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY SERVICES, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL NUCLEIC ACIDS FOR MOLECULAR DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MIL

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Nucleic Acids for Molecular Diagnosis market report include:
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • F. Hoffmann-La Roche Ltd.
  • Danaher Corporation
  • Abbott Laboratories
  • Bio-Rad Laboratories, Inc.
  • Merck KGaA
  • Agilent Technologies, Inc.
  • Hologic, Inc.
  • PerkinElmer, Inc.